REDWOOD CITY, Calif., May 05, 2025 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced that its first quarter 2025 financial results will be released after market close on Monday, May 12, 2025. Starting at 5:00 p.m. EDT on May 12, 2025, Coherus’ management team will host a conference call and webcast to discuss financial results and provide a general business update.

Read more:
Coherus to Report First Quarter 2025 Financial Results on May 12, 2025

Announced focused registrational clinical development plans for lead programs, extended cash runway, and accelerated/augmented corporate milestones

Read the original here:
ORIC® Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational Updates

~ uniQure to host inaugural earnings call on Friday, May 9, 2025 at 8:30 a.m. ET ~ ~ uniQure to host inaugural earnings call on Friday, May 9, 2025 at 8:30 a.m. ET ~

Continue reading here:
uniQure to Announce First Quarter 2025 Financial Results

Company Announces Strategic Realignment to Focus on Core Programs and Extend Cash Runway

More:
Biomea Fusion Reports First Quarter 2025 Financial Results and Corporate Highlights

RADNOR, Pa., May 05, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, today announced it will report its financial results from the first quarter ended March 31, 2025, after the financial markets close on Monday, May 12, 2025.

Link:
Mineralys Therapeutics to Announce First Quarter 2025 Financial Results and Host Conference Call on Monday, May 12, 2025

SAN FRANCISCO, May 05, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce first quarter 2025 financial results on Monday, May 12 after the markets close. FibroGen will also conduct a conference call on that day at 5:00 PM Eastern Time with the investment community to further detail the company's corporate and financial performance.

Originally posted here:
FibroGen to Report First Quarter 2025 Financial Results

- Progression-free survival data from more than 30 patients with first line pancreatic cancer in the ongoing Phase 2a trial of IMM-1-104 trial planned for announcement in 2Q’25 -

Continued here:
Immuneering Reports First Quarter 2025 Financial Results and Provides Business Updates

Board Member Dr. Karen Smith to serve as Interim Chief Medical Officer Board Member Dr. Karen Smith to serve as Interim Chief Medical Officer

See the rest here:
Context Therapeutics Announces Chief Medical Officer Transition

Cash runway extended into 2029

See the article here:
Relay Therapeutics Reports First Quarter 2025 Financial Results and Corporate Updates

Reiterates Full Year 2025 Financial Guidance Reiterates Full Year 2025 Financial Guidance

Continue reading here:
Certara Reports First Quarter 2025 Financial Results

SAN DIEGO, May 05, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today reported financial results for the first quarter ended March 31, 2025, and provided a business update.

See the article here:
Anaptys Announces First Quarter 2025 Financial Results and Provides Business Update

Châtillon, France, May 5, 2025

See original here:
DBV Technologies to Participate in the Citizens JMP Life Sciences Conference

HOLLISTON, Mass., May 05, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for the quarter ended March 31, 2025, before the market opens on May 12, 2025, and will hold a conference call to discuss the results at 8:00 a.m. Eastern Time.

The rest is here:
Harvard Bioscience Schedules First Quarter 2025 Earnings Conference Call for May 12, 2025 at 8:00 AM ET

A correction from source is being issued with respect to the press release titled, Firefly Neuroscience Achieves Multi-Fold Database, IP Portfolio, and Commercial Footprint Expansion Through Acquisition of Evoke Neuroscience, Inc., released on May 5, 2025 at 8:00 am ET. Please note, the correct form of payment of the potential Evoke investors’ earn-out is in Firefly’s common stock. The complete corrected press release follows:

More:
Correction From Source: Firefly Neuroscience Achieves Multi-Fold Database, IP Portfolio, and Commercial Footprint Expansion Through Acquisition of...

Not for distribution to U.S. news wire services or dissemination in the United States

Read more here:
Kane Biotech Announces Closing of Private Placement Offering and Loan with Insiders of the Company

Basel, Switzerland, 6 May 2025 – Novaremed AG, a privately held clinical-stage biopharmaceutical company, announces that recruitment is completed in the National Institutes of Health (NIH) -sponsored Phase 2b EN21-01 trial (ClinicalTrials.gov identifier NCT05480228). The study evaluates Novaremed’s non-opioid investigational drug NRD.E1 for the treatment of chronic pain associated with diabetic peripheral neuropathy, and is funded by the NIH Helping to End Addiction Long-term Initiative, or NIH HEAL Initiative. Topline Phase 2b data readout is expected in Q4 2025.

See original here:
Novaremed Announces Completion of Enrollment in NIH-sponsored Phase 2b Study with Non-opioid NRD.E1 for the Treatment of Chronic Pain Associated with...

May 6, 2025Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that Tim Van Hauwermeiren, Chief Executive Officer, and members of the management team will present at the BofA Securities 2025 Health Care Conference on Tuesday, May 13, 2025 at 4:20 p.m. PT.

View original post here:
argenx to Present at BofA Securities 2025 Health Care Conference

Basel, 06 May 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the launch of its Elecsys® PRO-C3 test, a new diagnostic solution designed to assess the severity of liver fibrosis in patients showing signs of metabolic dysfunction–associated steatotic liver disease (MASLD). The test, developed in partnership with Nordic Bioscience, offers clinicians a simple and efficient method of identifying patients with liver fibrosis of varying severity, enabling timely intervention and appropriate management of the disease.

Here is the original post:
Roche introduces innovative Elecsys PRO-C3 test to improve precision in evaluating liver fibrosis severity

Angelini Ventures marks its first investment in the cardiovascular and gene therapy space – and first in Asia, further diversifying its strong and growing portfolio

Continue reading here:
Angelini Ventures Co-Leads $45 Million Series B Financing of Nuevocor to Advance Transformative Treatment for Genetic Dilated Cardiomyopathy

PARIS, FRANCE, 06 May 2025 – Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty care-driven biopharmaceutical company, announced today the appointment of Laura Réveillon, PhD as EVP, Strategy & Transformation, effective May 14, 2025. She will serve on the Executive Leadership Team and report directly to Ipsen’s Chief Executive Officer (CEO), David Loew.

Excerpt from:
Ipsen appoints Laura Réveillon as EVP, Strategy & Transformation